Effect of Dispersion Medium on Pharmacokinetic Profile of Rotigotine Crystalline Suspension following Subcutaneous Injection
Rotigotine (RTG) is prescribed as a once-daily transdermal patch for managing early Parkinson’s disease (PD), which presents issues such as skin irritation and poor patient adherence. Therefore, the aims of the present study were to formulate aqueous and oily vehicle-based RTG crystalline suspension...
Main Authors: | Min Seop Kim, Myoung Jin Ho, Min Yeong Joung, Yong Seok Choi, Myung Joo Kang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/12/2630 |
Similar Items
-
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
by: Ronan Talty, et al.
Published: (2022-08-01) -
Effects of rotigotine on clinical symptoms, quality of life and sleep hygiene adequacy in hemodialysis-associated restless legs syndrome
by: Vicent Esteve, et al.
Published: (2018-01-01) -
BEHAVIORAL AND NEUROPHYSIOLOGICAL EFFECTS OF TRANSDERMAL ROTIGOTINE IN ATYPICAL PARKINSONISM
by: Davide v Moretti, et al.
Published: (2014-06-01) -
Design of Montelukast Nanocrystalline Suspension for Parenteral Prolonged Delivery
by: Park JS, et al.
Published: (2022-08-01) -
Fabrication, Optimization, and Evaluation of Rotigotine-Loaded Chitosan Nanoparticles for Nose-To-Brain Delivery
by: Angeline Shak. Tzeyung, et al.
Published: (2019-01-01)